Development asset linked to APREMEDA s.r.o in public FDA and regional records.
pharma · high blood pressure · increased blood clotting
APREMEDA s.r.o
s.r.o.
APREMEDA s.r.o drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
EU HQ
2020 Founded
18 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- EU
- Founded
- 2020
- Employees
- 18
- Programs
- 5
- Drugs
- 16
- Patents
- 0
APREMEDA s.r.o pipeline
Portfolio lens on 16 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
APREMEDA s.r.o drug portfolio — 16 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to APREMEDA s.r.o in public FDA and regional records.
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in APREMEDA s.r.o's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
Development asset linked to APREMEDA s.r.o in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
rivaroxaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
Development asset linked to APREMEDA s.r.o in public FDA and regional records.
-
Development asset linked to APREMEDA s.r.o in public FDA and regional records.
-
Development asset linked to APREMEDA s.r.o in public FDA and regional records.
-
Development asset linked to APREMEDA s.r.o in public FDA and regional records.
-
telmisartan
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
Development asset linked to APREMEDA s.r.o in public FDA and regional records.
-
Development asset linked to APREMEDA s.r.o in public FDA and regional records.